Zosano Pharma (NASDAQ:ZSAN) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.03, Fidelity Earnings reports.
ZSAN stock traded down $0.06 during trading on Friday, reaching $1.91. 287,800 shares of the company were exchanged, compared to its average volume of 876,576. The company has a 50-day moving average of $1.91 and a two-hundred day moving average of $2.60. The company has a market capitalization of $35.98 million, a price-to-earnings ratio of -0.51 and a beta of 2.67. Zosano Pharma has a twelve month low of $1.41 and a twelve month high of $6.65. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.22.
A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. BTIG Research lowered their price objective on shares of Zosano Pharma to $16.00 and set an “in-line” rating for the company in a research report on Friday. Cantor Fitzgerald lowered their price objective on shares of Zosano Pharma from $12.00 to $6.00 in a research report on Friday. Finally, ValuEngine upgraded shares of Zosano Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Zosano Pharma presently has an average rating of “Buy” and an average target price of $8.25.
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Read More: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.